Asston Pharmaceuticals IPO Debuts: Strong Listing Buzz as GMP Hints at Robust Gains

Unknown Apr 02, 2026 1,200 Views

Market Debut Today Asston Pharmaceuticals, a fast-growing player in the pharma export and manufacturing space, is set to make its debut on the BSE SME platform today. The IPO, which opened for subscription from July 9 to July 11, 2025, has generated significant excitement among inves...

Market Debut Today

Asston Pharmaceuticals, a fast-growing player in the pharma export and manufacturing space, is set to make its debut on the BSE SME platform today. The IPO, which opened for subscription from July 9 to July 11, 2025, has generated significant excitement among investors, with the grey market premium (GMP) signaling a healthy listing premium.

Key Highlights

The IPO was entirely a fresh issue, raising Rs 27.56 crore through 22.41 lakh shares at a price band of Rs 115 to Rs 123 per share.

The issue saw overwhelming demand, being oversubscribed by more than 170 times, with retail and HNI segments showing particularly strong interest.

The latest GMP stands at Rs 30, indicating an expected listing price of around Rs 153 per share, which translates to a premium of approximately 24 percent over the upper price band.

The company’s robust financials for FY25 include a 62 percent jump in revenue to Rs 25.61 crore and a 218 percent surge in profit after tax to Rs 4.33 crore.

Asston Pharmaceuticals is recognized for its diverse product portfolio, including tablets, syrups, capsules, and sachets, and holds certifications from central and state FDA, NQA, and adheres to QMS standards.

What Investors Should Know

The IPO proceeds will be used for capital expenditure, working capital, debt repayment, and general corporate purposes.

The minimum lot size for retail investors was 2,000 shares, requiring a minimum investment of Rs 2,46,000.

The company operates on both direct sales and contract manufacturing models, with a growing export footprint and a workforce of 52 employees.

Outlook

With a strong GMP, stellar subscription numbers, and robust financial growth, Asston Pharmaceuticals’ listing is expected to attract healthy investor interest. However, as with all SME IPOs, investors should remain mindful of potential volatility post-listing.

Sources: Economic Times, Chittorgarh, IPOWatch, Groww, Business Standard, Torus Digital, Shoonya, HDFC Sky

Stay Ahead – Explore Now! FOMO TO FMA - From Wall Street to Dalal Street: Global Risk Appetite Returns, Gold Hits New Highs and Oil Takes a Beating